Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

TARSUS PHARMACEUTICALS, INC. (TARS) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

TARSUS PHARMACEUTICALS, INC. (TARS), most recent 12 months reported: revenue $606.33M, net loss $46.48M, free cash flow $56M. Latest balance sheet on file: liquid cash $449.69M, total debt $72.76M, net cash $376.93M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): HALOZYME THERAPEUTICS, INC. · BIO-TECHNE Corp · BIOCRYST PHARMACEUTICALS, INC. · REPLIGEN CORP · ADMA BIOLOGICS, INC. · Krystal Biotech, Inc. · Twist Bioscience Corporation · Immunocore Holdings plc

Stock screener

Watchlist